Acute lymphoblastic leukemia, version 1.2019: Featured updates to the NCCN Guidelines Guidelines
| Authors: | Brown, P. A.; Wieduwilt, M.; Logan, A.; DeAngelo, D. J.; Wang, E. S.; Fathi, A.; Cassaday, R. D.; Litzow, M.; Advani, A.; Aoun, P.; Bhatnagar, B.; Boyer, M. W.; Bryan, T.; Burke, P. W.; Coccia, P. F.; Coutre, S. E.; Jain, N.; Kirby, S.; Liu, A.; Massaro, S.; Mattison, R. J.; Oluwole, O.; Papadantonakis, N.; Park, J.; Rubnitz, J. E.; Uy, G. L.; Gregory, K. M.; Ogba, N.; Shah, B. |
| Title: | Acute lymphoblastic leukemia, version 1.2019: Featured updates to the NCCN Guidelines |
| Abstract: | Survival outcomes for older adults with acute lymphoblastic leukemia (ALL) are poor and optimal management is challenging due to higher-risk leukemia genetics, comorbidities, and lower tolerance to intensive therapy. A critical understanding of these factors guides the selection of frontline therapies and subsequent treatment strategies. In addition, there have been recent developments in minimal/measurable residual disease (MRD) testing and blinatumomab use in the context of MRD-positive disease after therapy. These NCCN Guidelines Insights discuss recent updates to the NCCN Guidelines for ALL regarding upfront therapy in older adults and MRD monitoring/testing in response to ALL treatment. |
| Journal Title: | Journal of the National Comprehensive Cancer Network |
| Volume: | 17 |
| Issue: | 5 |
| ISSN: | 1540-1405 |
| Publisher: | Harborside Press |
| Date Published: | 2019-05-01 |
| Start Page: | 414 |
| End Page: | 423 |
| Language: | English |
| DOI: | 10.6004/jnccn.2019.0024 |
| PUBMED: | 31085755 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Source: Scopus |
